EaseVision.com – News and gossips of vision care and optical industry

It is reported that Abbott Laboratories is going to take another action to make an acquisition. The California-based eye-care device company named Visiogen Inc. will be sold in cash. Abbott buys Visiogen for business reasons.

Currently, the market of eye surgery devices and technology is estimated to be $20 billion in international sales every year. Abbott has clearly foreseen the potentially huge profit, so that its latest move targets at Visiogen, which specializes in developing vision devices for cataracts patients.

As the executive vice president of Abbott’s medical devices business, John Capek also expresses good confidence in this acquisition that Visiogen’s accommodating lens technology used to treat cataracts will improve Abbott’s ability in treating refractive visual errors. With Abbot’s new products, ophthalmologists can offer a wider variety of refractive options for their patients.

In fact, this is not the only acquisitive action in Abbott. The firm has just acquired Advanced Medical Optics earlier this year, which is a firm manufacturing eye surgery care equipments. This earlier acquisition directly cost Abbott more than $ 1.3 billion. Within such a short period after a great acquisition, Abbott is now planning to purchase Visiogen.

All of these moves show Abbott’s long-term view and confidence in the vision care and technology industry. The promising company aims at improving the living standards of the millions in the world by creating and innovating visual technologies.

Asos Chicos